218 related articles for article (PubMed ID: 29017215)
1. [Pulmonary Embolism Despite Rivaroxaban in an Obese Patient].
Schuh T; Stöllberger C
Dtsch Med Wochenschr; 2017 Oct; 142(20):1548-1551. PubMed ID: 29017215
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary embolism four days after interruption of therapy with rivaroxaban.
Göndör G; Stöllberger C
Hamostaseologie; 2017 Oct; 37(4):302-306. PubMed ID: 28853765
[TBL] [Abstract][Full Text] [Related]
4. Management, control, and decision making in unexpected recurrent venous thromboembolism in COVID-19: a case report.
Zolfaghari Emameh R; Heshmatnia J
J Med Case Rep; 2023 Mar; 17(1):101. PubMed ID: 36934279
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary approach to the management of patients with pulmonary embolism and deep vein thrombosis: a consensus on diagnosis, traditional therapy and therapy with rivaroxaban.
Imberti D; Becattini C; Bernardi E; Camporese G; Cuccia C; Dentali F; Paretti D
Intern Emerg Med; 2018 Oct; 13(7):1037-1049. PubMed ID: 29520700
[TBL] [Abstract][Full Text] [Related]
6. Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome.
Yagi S; Nishiyama S; Abe T; Sata M
BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30635311
[TBL] [Abstract][Full Text] [Related]
7. Practical management of rivaroxaban for the treatment of venous thromboembolism.
Imberti D; Benedetti R
Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
9. Morbidly Obese Patient on Rivaroxaban Presents With Recurrent Upper Extremity Deep Vein Thrombosis: A Case Report.
Jennings ST; Manh KNP; Bita J
J Pharm Pract; 2020 Oct; 33(5):712-719. PubMed ID: 31232154
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Venous Thromboembolism in Two Patients With Cancer Taking Rivaroxaban.
Theodorou JM; Patel Y; Ford P
J Pharm Pract; 2017 Jun; 30(3):381-384. PubMed ID: 27026636
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
[TBL] [Abstract][Full Text] [Related]
12. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
13. Elevated D-dimer concentration identifies patients with incomplete recanalization of pulmonary artery thromboemboli despite 6 months anticoagulation after the first episode of acute pulmonary embolism.
Kaczyńska A; Kostrubiec M; Pacho R; Kunikowska J; Pruszczyk P
Thromb Res; 2008; 122(1):21-5. PubMed ID: 17931694
[TBL] [Abstract][Full Text] [Related]
14. Management of pulmonary embolism after recent intracranial hemorrhage: A case report.
Lee WC; Fang HY
Medicine (Baltimore); 2018 Apr; 97(15):e0479. PubMed ID: 29642222
[TBL] [Abstract][Full Text] [Related]
15. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.
Myzienski AE; Lutz MF; Smythe MA
Pharmacotherapy; 2010 Mar; 30(3):324. PubMed ID: 20180615
[TBL] [Abstract][Full Text] [Related]
16. Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: an analysis of the implications for perioperative management.
Mookadam M; Shamoun FE; Ramakrishna H; Obeid H; Rife RL; Mookadam F
Ann Card Anaesth; 2015; 18(4):517-27. PubMed ID: 26440238
[TBL] [Abstract][Full Text] [Related]
17. Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.
Duan L; Zhang N; Yan H; Guo Y; Hong C; Yang X; Su X; Chen R; Zhou Y; Zhong N; Liu C
Clin Chim Acta; 2016 Aug; 459():25-29. PubMed ID: 27155586
[TBL] [Abstract][Full Text] [Related]
18. Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy.
Stöllberger C; Finsterer J
Neurol Neurochir Pol; 2017; 51(2):194-196. PubMed ID: 28215696
[TBL] [Abstract][Full Text] [Related]
19. [The optimal duration of anticoagulant treatment following pulmonary embolism].
Couturaud F
Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
[TBL] [Abstract][Full Text] [Related]
20. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Patel AA; Ogden K; Mody SH; Bookhart B
J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
